Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with up to 12 additional months of follow-up. The trial design, including a randomized withdrawal phase, allows for meaningful assessment of both sustained benefit and dependence on continued treatment. Results from this rigorously controlled study will provide some of the highest-quality clinical evidence to date on cannabis-based therapy for one of the most prevalent and undertreated pain conditions globally.
#2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by evaluating a full-spectrum cannabis extract as an alternative to conventional analgesics and opioids, which have limited efficacy and significant adverse effect profiles in chronic low back pain management. The robust design with 820 participants and rigorous methodology provides the level of evidence needed to inform clinical decision-making regarding cannabis-based therapeutics for one of the most prevalent pain conditions globally. Positive efficacy and safety data would support evidence-based integration of this treatment into multimodal pain management strategies and potentially reduce reliance on medications with greater abuse and dependence liability.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial presents encouraging data for a full-spectrum cannabis extract in chronic low back pain, a condition where conventional pharmacotherapy often disappoints patients and clinicians alike. However, several important caveats warrant careful interpretation: the study appears to have incomplete reporting in the provided abstract, we lack visibility into effect sizes and clinical meaningfulness of any observed differences, and full-spectrum extracts introduce variability in cannabinoid ratios and minor constituent profiles that may limit reproducibility across different formulations or patient populations. The open-label extension phase raises concerns about bias, as unblinded continuation typically inflates perceived benefit through expectancy effects and regression to the mean. For clinical practice, while this trial adds to the growing body of evidence supporting cannabis consideration in refractory CLBP, providers should remain appropriately skeptical of effect magnitude claims until detailed results are published, and should continue individualizing therapy by starting low-dose, monitoring response objectively, and integrating cannabis within multimodal pain management rather than viewing it as a standalone solution
| |